SUMMARY

• Janssen does not recommend the use of TALVEY in a manner that is inconsistent with the approved labeling.
• Infections have been reported as an adverse event (AE) in the MonumenTAL-1, MonumenTAL-2, TRIMM-2, and RedirecTT-1 studies.^1-7
• MonumenTAL-1 (MMY1001) is an ongoing, open-label, phase 1/2 study evaluating the efficacy and safety of TALVEY in patients with relapsed or refractory multiple myeloma (RRMM) after ≥3 prior lines of therapy (LOTs), including a proteasome inhibitor (PI), an immunomodulatory drug, and an anti-CD38 monoclonal antibody.^1,4,8-10
  • Schinke et al (2024)¹¹ presented the incidence of infections from a subgroup analysis in Black and White patients at a median follow-up of 26 months for the Black subgroup and 31 months for the White subgroup. The subgroup of patients received TALVEY at the recommended phase 2 doses (RP2Ds) of 0.4 mg/kg subcutaneous (SC) weekly (QW) and 0.8 mg/kg SC every other week (Q2W).
  • Rasche et al (2024)¹² presented the incidence of infections from the MonumenTAL-1 study at a median follow-up of 29.8 months for the 0.4 mg/kg SC QW cohort, 23.4 months for the 0.8 mg/kg SC Q2W cohort, and 20.5 months for the prior T-cell redirection (TCR) cohorts.
  • Chari et al (2024)¹³ published the clinical management of AEs in patients with RRMM treated with TALVEY in the MonumenTAL-1 study. Infections were reported in the QW, Q2W, and TCR cohorts.
  • Jakubowiak et al (2023)¹⁴ presented the incidence of infections in patients with prior TCR, including an additional 19 patients enrolled in the MonumenTAL-1 study since the prior analysis, at a median follow-up of 18.4 months for the overall prior TCR cohort, 18.4 months for the prior chimeric antigen receptor modified T-cells (CAR-T) cohort, and 16.3 months for the prior bispecific antibody (BsAb) cohorts.
  • Rodriguez-Otero et al (2023)¹⁵ presented data on infections and immune function from the MonumenTAL-1 study at a median follow-up of 18.8 months for the 0.4 mg/kg SC QW cohort, 12.7 months for the 0.8 mg/kg SC Q2W cohort, and 14.8 months for the prior TCR cohort.
  • Chari et al (2022)^4,5 published the incidence of infections in the phase 1 portion of the MonumenTAL-1 study. Patients received TALVEY at the first RP2D of 0.405 mg/kg SC QW (median follow-up, 11.7 months), or at the second RP2D of 0.8 mg/kg SC Q2W (median follow-up, 4.2 months).
  • As per the MonumenTAL-1 study (part 3) protocol, infectious complications were treated with oral, or intravenous (IV) antibiotics or other anti-infective agents as considered appropriate by the treating investigator for a given infectious condition, according to standard institutional practice.⁸
• MonumenTAL-2 (MMY1004) is an ongoing, phase 1b, multi-arm, open-label study evaluating TALVEY in combination with other anticancer therapies in patients with multiple myeloma (MM).^6,16
  • Cohort D is evaluating the efficacy and safety of TALVEY + DARZALEX FASPRO^® + lenalidomide in 34 patients with newly diagnosed multiple myeloma (NDMM).¹⁷
    • Nooka et al (2024)¹⁷ presented the incidence of infections in the TALVEY 0.6 mg/kg Q2W + DARZALEX FASPRO + lenalidomide cohort at a median follow-up of 13.2 months (range, 10.0-14.6) and the TALVEY 0.8 mg/kg every 4 weeks (Q4W) + DARZALEX FASPRO + lenalidomide cohort at a median follow-up of 5.8 months (range, 1.7 [denotes patients who died]-12.0).
  • Cohort E is evaluating the safety and efficacy of TALVEY + pomalidomide in 35 patients with RRMM.¹⁸
    • Searle et al (2024)¹⁸ presented the incidence of infections in the TALVEY + pomalidomide cohort from the MonumenTAL-2 study at a median follow-up of 16.8 months (range, 1.2-25.1).
• RedirecTT-1 (MMY1003) is an ongoing, open-label, phase 1b/2 study evaluating the safety and efficacy of TALVEY and TECVAYLI in patients with RRMM.^3,7,19,20
  • Cohen et al (2025)^7,21 published the incidence of infections from the phase 1 dose-escalation segment of the RedirecTT-1 study at a median follow-up of 20.3 months (range, 0.5-37.1) in the all dose levels (dose levels 1-5) cohort.
• TRIMM-2 (MMY1002) is an ongoing, phase 1b, multicohort open-label study evaluating the efficacy and safety of DARZALEX FASPRO in combination with TECVAYLI^® or TALVEY with or without pomalidomide in patients with RRMM.^2,22,23
  • Bahlis et al (2024)²³ presented the incidence of infections in the TALVEY 0.4 mg/kg QW + DARZALEX FASPRO + pomalidomide cohort at a median follow-up of 15.8 months (range, 3.2-37.9) and TALVEY 0.8 mg/kg Q2W + DARZALEX FASPRO + pomalidomide cohort at a median follow-up of 17.5 months (range, 0.2-37.7).
• Other relevant literature has been identified in addition to the data summarized above:
  • Nursing and advance practice practitioner’s considerations for management of infections.²⁴

PRODUCT LABELING

• TALVEY (talquetamab-tgvs) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TALVEY-pi.pdf.
• DARZALEX FASPRO (daratumumab and hyaluronidase-fihj) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/DARZALEX+Faspro-pi.pdf.
• TECVAYLI (teclistamab-cqyv) [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.; https://www.janssenlabels.com/package-insert/product-monograph/prescribing-information/TECVAYLI-pi.pdf.

CLINICAL DATA - Monumental-1 Study

MonumenTAL-1 (MMY1001; NCT03399799, NCT04634552) is a phase 1/2 study of TALVEY in patients with RRMM.^9,10

The study was conducted in 3 parts; the primary objectives are listed below¹:

• Part 1 (phase 1; dose escalation): to characterize the safety of TALVEY and determine the RP2Ds and schedule.
• Part 2 (phase 1; dose expansion): to further characterize the safety of TALVEY at the RP2Ds.
• Part 3 (phase 2): to evaluate the efficacy of TALVEY at the RP2Ds.

Study Design/Methods (Phase 2)

Patients were enrolled into 1 of the following 3 cohorts^1,14:

• TCR naïve: 0.4 mg/kg SC QW, not previously exposed to TCR such as CAR-T therapy or BsAbs (prior B-cell maturation antigen [BCMA] antibody-drug conjugate [ADC] allowed).
• TCR naïve: 0.8 mg/kg SC Q2W, not previously exposed to TCRs (prior BCMA ADC allowed).
• Prior TCR: 0.4 mg/kg SC QW or 0.8 mg/kg SC Q2W, have been previously exposed to TCRs.
  • Among the prior TCR-exposed cohort, patients were divided based on the type of TCR (CAR-T, BsAb, or CAR-T and BsAb).
• Key eligibility criteria (Part 3; Phase 2):
  • Measurable MM.¹⁴
  • ≥3 prior LOTs including a PI, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.¹⁴
  • Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2.¹⁴
• Key exclusion criteria (Part 3; Phase 2):
  • Prior grade 3 or higher cytokine release syndrome (CRS; per Lee criteria 2014²⁵) related to any TCR or any prior G protein-coupled receptor class C group 5 member D (GPRC5D)-targeting therapy.⁸
  • Received cumulative dose of corticosteroids equivalent to ≥140 mg of prednisone within 14 days prior to study drug (not including premedication).⁸
• Primary endpoint: overall response rate (ORR).¹
• Key secondary endpoints: duration of response (DOR), progression-free survival (PFS), overall survival, safety, immunogenicity, and pharmacodynamics.¹

Schinke et al (2024)¹¹ presented the incidence of infections from a subgroup analysis in Black patients who received TALVEY at the RP2Ds of 0.4 mg/kg SC QW and 0.8 mg/kg SC Q2W in phase 1/2 of the MonumenTAL-1 study at a median follow-up was 26 months for the Black subgroup and 31 months for the White subgroup.

Safety Results

• Details on infection-related AEs are summarized in Table: MonumenTAL-1 Study: Summary of Infections in Black vs White Patients.

Rasche et al (2024)¹² presented the incidence of infections from the MonumenTAL-1 study at a median follow-up of 29.8 months for the 0.4 mg/kg SC QW cohort, 23.4 months for the 0.8 mg/kg SC Q2W cohort, and 20.5 months for the prior TCR cohorts.

Safety Results

• At a longer follow-up, no increase in grade 3/4 infections was observed. Incidence of infections in Q2W cohort is detailed in Figure: New-Onset Grade ≥3 Infections Over Time in the Q2W Cohort.
• IV immunoglobulin (IVIG) was required in 16%, 14%, and 24% of patients in the QW, Q2W, and prior TCR cohorts, respectively.

Chari et al (2024)¹³ published the clinical management of AEs in patients with RRMM treated with TALVEY in the MonumenTAL-1 study. Results specific to infection events are summarized below.

Safety Results

• A summary of infections associated with TALVEY in MonumenTAL-1 is presented in Table: MonumenTAL-1 Study: Infections Associated With TALVEY.
• The most frequently reported any-grade infections were Coronavirus Disease 2019 (COVID-19), upper respiratory tract infections, nasopharyngitis, urinary tract infections, bronchitis, and pneumonia.
  • The most common grade 3/4 infections (requiring invasive or urgent intervention per Common Terminology Criteria for Adverse Events [CTCAE] classification) were pneumonia, urinary tract infections, COVID-19, sepsis, and cellulitis.
  • Most high-grade infections occurred during the first 100 days of treatment.
• No cases of pneumocystis pneumonia were reported.
• Treatment discontinuation due to infections was reported in 2 patients in the 0.4 mg/kg SC QW cohort and 1 patient in the prior TCR cohort.
• A total of 5 (1.5%) patients died from infections (COVID-19 pneumonia, n=2; 1 patient each due to septic shock, fungal sepsis, and infection).

Supportive Measures/Management

• In MonumenTAL-1, medications given most commonly for infections were antibiotics, with some use of antifungals, anticholinergics, and glucocorticoids. See Table: MonumenTAL-1 Study: Most Common Supportive Measures and Concomitant Treatments for Infections.
• Infection prophylaxis was used in patients receiving TALVEY.
  • Acyclovir was the most common prophylactic medication used in the MonumenTAL-1 study for infections and given to 52.4%, 71.7%, and 74.5% of patients in the 0.4 mg/kg QW, 0.8 mg/kg Q2W, and prior TCR cohorts, respectively.
  • Valaciclovir was the second most common form of prophylaxis and given to 37.1%, 11.0%, and 17.6% of patients in the 0.4 mg/kg QW, 0.8 mg/kg Q2W, and prior TCR cohorts, respectively.
  • Antibacterial prophylaxis may be beneficial in patients with an elevated risk of developing infections. Antifungal prophylaxis should be considered if patients have undergone treatment with high-dose or prolonged use of corticosteroids.
  • Filgrastim should be considered to manage neutropenia.
• New infections often occurred in early treatment cycles, suggesting the need for more aggressive infection prevention until cytopenia recovers.
• Vaccinations are still expected to be effective as patients treated with TALVEY showed preservation of humoral immune function and no decreases in B cells or polyclonal IgG levels.
  • Vaccines should be given before starting treatment, though this may not always be possible, such as for annual influenza and COVID-19 vaccinations.
• Testing for cytomegalovirus and Epstein-Barr virus is recommended for patients with unexplained fever or unexplained symptoms, such as weight loss, extreme fatigue, and diarrhea.
• Monitoring for hypogammaglobulinemia and administration of IVIG are crucial for preventing and managing infections during novel antibody treatment, including TALVEY.
  • IVIG use should be considered for patients with hypogammaglobulinemia and recurrent infections. Based on investigator experience, it can also be administered on the same day as TALVEY after the CRS risk period has elapsed.
• During step-up dosing (SUD) and early treatment cycles, fever should be evaluated to distinguish between CRS and infection, as symptoms may overlap.
• Temporarily interrupting dosing to allow infections to resolve before resuming TALVEY is also a key part of infection management.

Jakubowiak et al (2023)¹⁴presented the incidence of infections in patients with prior TCR, including an additional 19 patients enrolled in the MonumenTAL-1 study since the prior analysis, at a median follow-up of 18.4 months for the overall prior TCR cohort and the prior CAR-T cohort and 16.3 months for the prior BsAb cohort.

Safety Results

• A summary of AEs specific to infections in patients with prior TCR is presented in Table: MonumenTAL-1 Study: Infections (Prior TCR).
  • Patients with prior exposure to CAR-T had similar rates of infections when compared with patients with prior exposure to BsAb.

Rodriguez-Otero et al (2023)¹⁵ presented data on infections and immune function from the phase 2 portion of the MonumenTAL-1 study at a median follow-up of 18.8 months for the 0.4 mg/kg SC QW cohort, 12.7 months for the 0.8 mg/kg SC Q2W cohort, and 14.8 months for the prior TCR cohort.

Safety Results

• Any-grade infections were reported in 64.0% of patients, of whom 18.6% had grade 3/4 infections. In total, infections led to death of 1.5% (n=5) of patients. See Table: MonumenTAL-1 (Phase 2) Study: Summary of Infections.
• In the 0.4 mg/kg SC QW, 0.8 mg/kg SC Q2W, and prior TCR cohorts, hypogammaglobulinemia or postbaseline IgG level of <500 mg/dL was reported in 64.3%, 67.6%, and 72.5% of patients, respectively.
  • In the 0.4 mg/kg QW, 0.8 mg/kg Q2W, and prior TCR cohorts, IVIG was administered to 14.7%, 13.1%, and 15.7% of patients, respectively.
• New-onset grade 3/4 infections were the most prevalent during the first 100 days in all 3 cohorts. Across clinically relevant infections, the most common were respiratory infections and COVID-19 (cases of COVID-19 were irrespective of the causal relation to TALVEY).
• Neutrophil counts decreased during cycle 1 but recovered steadily from cycle 2.
• No reduction in the levels of CD19+ B cells was observed over time, with an increasing trend noted at cycle 7.
• No decrease in polyclonal IgG over time was reported across cohorts.

Chari et al (2022)⁴ published the incidence of infections from the phase 1 portion of the MonumenTAL-1 study at a median follow-up of 11.7 months (range, 1.0-21.2) for the 0.405 mg/kg SC QW cohort and 4.2 months (range, 0.7-13.7) for the 0.8 mg/kg SC Q2W cohort.

Study Design/Methods

• Patients received TALVEY at a dose of 0.0005-0.18 mg/kg IV QW or Q2W, at the first RP2D of 0.405 mg/kg SC QW, or at the second RP2D of 0.8 mg/kg SC Q2W.
• Additional IV and SC doses were evaluated in order to determine the RP2Ds.

Safety Results

• Among patients who had received 0.405 mg/kg SC QW (n=30) and 0.8 mg/kg SC Q2W (n=44), infections occurred in 47% (grade 3/4 infections in 7% [n=2]) and 34% (grade 3/4 infections in 7% [n=3]), respectively.
• Additional details regarding grade ≥3 infections for the 0.405 mg/kg SC QW and 0.8 mg/kg SC Q2W cohorts are presented in Table: MonumenTAL-1 (Phase 1) Study: Grade ≥3 Infections.
• Opportunistic infections occurred in 2 patients who had received 0.405 mg/kg SC QW and 0.8 mg/kg SC Q2W, respectively. See Table: MonumenTAL-1 (Phase 1) Study: Opportunistic Infections for additional details.
  • No cytomegalovirus reactivation occurred.
• COVID-19 occurred in 13% and 2% of patients who received 0.405 mg/kg SC QW and 0.8 mg/kg SC Q2W, respectively.
  • No COVID-19 related deaths were reported.
• In the 0.405 mg/kg SC QW and 0.8 mg/kg SC Q2W cohorts, hypogammaglobulinemia, reported as a postbaseline IgG level of <500 mg/dL, occurred in 87% and 71% of patients, respectively.

MonumenTAL-1 Study Protocol Part 3 - Description and Management of Infections

Key Permitted Medications Related to Infections

• Patients are to receive full supportive care during the study. The following are examples of supportive therapies related to infections that may be used during the study:
  • Growth factor support was permitted to treat symptoms or signs of neutropenia according to local standards of care.⁸ Of note, the use of myeloid growth factors, particularly granulocyte macrophage-colony stimulating factor (GM-CSF), should be avoided during CRS.²⁶
  • Infectious complications were treated with oral or IV antibiotics or other anti-infective agents as considered appropriate by the treating investigator for a given infectious condition, according to standard institutional practice.⁸

Anticipated Benefits and Risks

• The presence of infections was frequently monitored by obtaining cultures and implementing empiric antibiotic therapy as appropriate.⁸
• Hepatitis B virus (HBV) and hepatitis C virus (HCV) infections were screened and monitored clinically as indicated, and treatment was initiated as appropriate.⁸
• In case of hypogammaglobulinemia, Ig levels were monitored throughout and after treatment.⁸
• Hypogammaglobulinemia was treated according to the local guidelines, including administration of Ig replacement and monitoring for infections.⁸

Dose Modification Guidance

• In the case of grade 3 neutropenia with infection, the dose was delayed in part 3 of the study.⁸

CLINICAL DATA - Monumental-2 study

MonumenTAL-2 (MMY1004; clinicaltrials.gov identifier NCT05050097) is an ongoing, phase 1b, multi-arm, open-label study evaluating TALVEY in combination with other anticancer therapies in patients with MM.^6,16-18

Study Design/Methods

• Key eligibility criteria:
  • Cohort D: measurable MM, NDMM, ECOG PS of 0-1, and transplant ineligible or not intended for transplant.^16,17
  • Cohort E: measurable MM, ≥2 prior LOTs, including a PI and an immunomodulatory drug, ECOG PS of 0-1, prior pomalidomide and prior TCR (CAR-T and BsAb) permitted, and no prior GPRC5D-targeted therapy.^16,18
• Primary endpoint for Cohort D and Cohort E: safety; AEs assessed per CTCAE v5.0, except for CRS and immune effector cell-associated neurotoxicity syndrome, which were graded per American Society for Transplantation and Cellular Therapy (ASTCT) guidelines.^16-18

Cohort D

Nooka et al (2024)¹⁷ presented the incidence of infections in the TALVEY 0.6 mg/kg Q2W + DARZALEX FASPRO + lenalidomide cohort at a median follow-up of 13.2 months (range, 10.0–14.6) and the TALVEY 0.8 mg/kg Q4W + DARZALEX FASPRO + lenalidomide cohort at a median follow-up of 5.8 months (range, 1.7 [denotes patients who died]-12.0).

Safety Results

• Details on infections are summarized in Table: MonumenTAL-2 Study (Cohort D): Summary of Infections.
• Hypogammaglobulinemia was reported in 63% and 54% of patients in the TALVEY 0.6 mg/kg Q2W + DARZALEX FASPRO + lenalidomide and TALVEY 0.8 mg/kg Q4W + DARZALEX FASPRO + lenalidomide cohorts, respectively; 50% and 19% of these patients received ≥1 IVIG during treatment, respectively.
• The most commonly reported infections were COVID-19, rhinovirus, and other upper respiratory tract infections.

Cohort E

Searle et al (2024)¹⁸ presented the incidence of infections in the TALVEY + pomalidomide cohort from the MonumenTAL-2 study at a median follow-up of 16.8 months (range, 1.2-25.1).

Safety Results

• TEAEs in ≥25% of patients were reported at a data cutoff date of April 22, 2024.
• The most common infections (mostly grade 1/2) were pneumonia, upper respiratory tract infections, and COVID-19.
  • First-onset infections generally occurred in the first few cycles of treatment.
• Any-grade infections were reported in 80% (n=28) of patients and grade 3/4 infection in 22.9% (n=8) of patients.

CLINICAL DATA - redirectt-1 STUDY - TALVEY + tecvayli COHORT

RedirecTT-1 (MMY1003; clinicaltrials.gov identifier: NCT04586426) is an ongoing, open-label, phase 1b/2 study evaluating the safety and effectiveness of the combination of TALVEY and TECVAYLI in patients with RRMM.^3,7,19,20

Study Design/Methods

• Key inclusion criteria: relapsed or refractory or intolerant to established therapies including the last LOT, prior exposure to a PI, an immunomodulatory drug, and an anti-CD38 monoclonal antibody.²⁰
• Primary endpoints: dose limiting toxicity and ORR.^7,20

Cohen et al (2025)^7,21 published the incidence of infections from the phase 1 dose-escalation segment of the RedirecTT-1 study reported in the all-dose-level cohort at a median follow-up of 20.3 months (range, 0.5-37.1) and in the RP2R cohort at 18.2 months.

Safety Results

Infections

• At a data cutoff of March 15, 2024, infections were reported. See Table: RedirecTT-1 Study (TALVEY + TECVAYLI Cohort): Infections (≥5% Overall) for additional details.^7,20,21
• Across all dose levels, the incidence of first onset of grade ≥3 infections was higher in the first 6 months of study treatment and then plateaued. The timing of the first onset of grade ≥3 infections is shown in Table: RedirecTT-1 Study (TALVEY + TECVAYLI Cohort): Timing of First Onset of Grade ≥3 Infections in Patients Across All Dose Levels.^7,21
• Infection prophylaxis was administered as per institutional guidelines. A total of 82% of patients (n=77) across all dose levels received antiviral prophylaxis, and 49% of the patients (n=46) received prophylaxis against Pneumocystis jirovecii pneumonia.^7,21
• In total, 63% of patients (n=59) received a COVID-19 vaccine.⁷
• Immunoglobulin replacement therapy (0.4 g/kg every 3-6 weeks) was recommended to maintain serum immunoglobulin G (IgG) levels above 400 mg/dL, regardless of current or past infections, with monitoring recommended at least every 3 months after reaching steady state.²¹
• Immunoglobulin replacement was provided per institutional guidelines for managing serious, recurrent, or chronic infections.²¹
• Deaths due to infections were reported in 11.7% of patients (n=11) in the all dose levels cohort and 6.8% of patients (n=3) in the RP2R cohort.^7,21

Hypogammaglobulinemia

• At baseline, 56% of patients across all dose levels (n=53) had non-IgG myeloma.⁷
  • Of these patients, 70% of patients (n=37) had hypogammaglobulinemia (defined as IgG <400 mg/dL) at baseline and 57% of patients (n=30) had post-treatment hypogammaglobulinemia.⁷
• The assessments excluded patients with IgG myeloma and those who received intravenous immunoglobulin (IVIG) replacement.⁷
• A total of 57% of patients (n=30) with non-IgG myeloma received IVIG.⁷
• A patient experienced grade 2 John Cunningham (JC) virus infection on day 163, PD on day 170 (when the patient discontinued TALVEY and TECVAYLI), and died on day 217 from grade 5 JC virus infection.²¹
  • This patient’s baseline IgG value was 248 g/dL; the patient had hypogammaglobulinemia with no IVIG administered and experienced intermittent neutropenia prior to the AE.²¹

CLINICAL DATA - TRIMM-2 STUDY

TRIMM-2 (MMY1002; clinicaltrials.gov identifier: NCT04108195) is an ongoing, phase 1b, 2-part, multicohort, open-label study evaluating DARZALEX FASPRO regimens in combination with bispecific TCR antibodies with or without pomalidomide in patients with RRMM.^2,22,23

Study Design/Methods

• Key eligibility criteria²:
  • Double refractory to a PI and an immunomodulatory drug or received ≥3 prior LOTs (including a PI and an immunomodulatory drug).
  • Treatment with an anti-CD38 monoclonal antibody (>90 days prior allowed), including anti-CD38 refractory patients.
  • Prior BsAb and CAR-T were allowed.
• Key primary endpoints²:
  • Part 1: identify the RP2D for each treatment combination.
  • Part 2: safety and tolerability at the selected RP2D of each treatment combination.
  • Antitumor activity.

Bahlis et al (2024)²³ presented the incidence of infections in the TALVEY 0.4 mg/kg QW + DARZALEX FASPRO + pomalidomide cohort at a median follow-up of 15.8 months (range, 3.2-37.9) and the TALVEY 0.8 mg/kg Q2W + DARZALEX FASPRO + pomalidomide cohort at a median follow-up of 17.5 months (range, 0.2-37.7).

Safety Results

• Among patients with grade 3/4 infections, 84.0% had onset within the first 6 months.
• IgG <400 mg/dL was reported in 33.8% of patients at baseline and 72.7% of patients after treatment; 53.2% of these patients received ≥1 dose of IVIG.
• The incidences of grade 3/4 and any-grade infections are presented in Table: TRIMM-2 Study (TALVEY + DARZALEX FASPRO + Pomalidomide Cohort): Infections (≥10% Overall).

Dholaria et al (2023)² presented the incidence of infections in the TRIMM-2 study for the TALVEY 0.4 mg/kg QW + DARZALEX FASPRO 1800 mg Q4W cohort at a median follow-up of 16.8 months (range, 1.9-31.0) and the TALVEY 0.8 mg/kg Q2W + DARZALEX FASPRO 1800 mg Q4W cohort at a median follow-up of 15.0 months (range, 1.0-23.3).

Safety Results

• Among patients that reported grade ≥3 infections, 75% experienced onset within the first 6 months.
• The incidences of grade 3/4 and any-grade infections in patients receiving TALVEY 0.4 mg/kg QW SC + DARZALEX FASPRO and TALVEY 0.8 mg/kg Q2W + DARZALEX FASPRO are presented in Table: TRIMM-2 Study (TALVEY + DARZALEX FASPRO Cohort): Infections (≥5%).

Infection Description in Both Cohorts

• Antibacterial, antifungal, or antiviral prophylaxis was given to 95.4% of patients.
• Opportunistic infections occurred in 10.8% of patients.
• Cytomegalovirus reactivation occurred in 3.1% of patients.
• One patient died of treatment-related pneumonia (TALVEY 0.8 mg/kg SC Q2W + DARZALEX FASPRO).
• IgG levels of <500 mg/dL were reported in 35.4% of patients at baseline and increased to 86.2% postbaseline, of whom 33.8% got IVIG.

literature Search

A literature search of MEDLINE^®, Embase^®, BIOSIS Previews^®, and Derwent Drug File databases (and/or other resources, including internal/external databases) topic was conducted on 12 February 2025.